EE651 Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in the First-Line Treatment of Patients With Metastatic Triple-Negative Breast Cancer in Greece
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.890
https://www.valueinhealthjournal.com/article/S1098-3015(22)03094-7/fulltext
Title :
EE651 Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in the First-Line Treatment of Patients With Metastatic Triple-Negative Breast Cancer in Greece
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)03094-7&doi=10.1016/j.jval.2022.09.890
First page :
Section Title :
Open access? :
No
Section Order :
10433